Strategic Cooperation Agreement Between Zhenshi Biotechnology and Yeedozencom on All-round Cooperation in R&D of Innovative Drugs and Generic Drugs
Henan Zhenshi Biotechnology Co., Ltd. (hereinafter referred to as “Zhenshi Biotechnology”) and Beijing Yeedozencom Health Technology Co., Ltd. (hereinafter referred to as “Yeedozencom”) entered into a strategic cooperation agreement on Jul. 4, 2019 to establish the all-round partnership in terms of the research and development of innovative drugs and generic drugs.
The strategic partnership marks the win-win cooperation of both sides in the field of drug research and development. The superiorities of Zhenshi Biotechnology in the research, development and industrialization of innovative drugs and the extensive experience and powerful technical strength of Yeedozencom in the Contract Research Organization (CRO) will greatly contribute to their sustainable research and cooperation in the future, stimulating the drug R&D and industrialization of Zhenshi Biotechnology and benefiting the patients as soon as possible!
After the signing ceremony, the technical seminar was held for the purpose of the special discussions on the Phase I clinical trials of antineoplastic drugs and the expansive indications of anti-HIV drugs.
Mr. Wang Chaoyang (Chairman, Zhenshi Biotechnology), Dr. Du Jinfa (CEO & CSO, Zhenshi Biotechnology), Mr. Guo Mintong (R&D Consultant, Zhenshi Biotechnology), Mr. Liu Yong (Executive Deputy General Manager, Zhenshi Biotechnology), Mr. Guo Changyue (Deputy General Manager, Zhenshi Biotechnology), Mr. Wang Xiang (Deputy General Manager, Zhenshi Biotechnology), Mr. Wu Zhi’ang (Chairman, Yeedozencom), Mr. Ling Yun (General Manager, Yeedozencom), Mr. Zhang Ruoming (Executive Deputy General Manager, Yeedozencom), Mr. Chen Zhen (Deputy General Manager & CSO, Yeedozencom) and other representatives attended the signing ceremony.
About Zhenshi Biotechnology
Established in 2012, Henan Zhenshi Biotechnology Co., Ltd. is a pharmaceutical sector controlled by Beijing Xingyu Investment (Group). As a commercial bio-pharmaceutical enterprise in the clinical stage, Zhenshi Biotechnology commits itself to the research, development and manufacture of the drugs against virus, tumor, cardiovascular and cerebrovascular diseases and hepatic diseases, etc. Its powerful R&D team includes 2 experts enrolled in the Recruitment Program of Global Experts, 1 member honored as the Leading Talent of Scientific and Technological Innovation of the National Special Support Program for High-level Talent Recruitment and 1 member honored as the National Distinguished Young Scholar. There are 12 R&D personnel of master degree, doctor degree and above. Zhenshi Biotechnology has an Operating Center in Beijing and a pharmaceutical industrial park (floor area of 220mu and total investment of CNY 700,000,000) under plan in the New Urban District of Pingdingshan City, which is expected to be the core industrialization base for innovator drugs upon coming into service.
Azvudine, an oral anti-AIDS drug newly developed by Zhenshi Biotechnology with the independent intellectual property rights, has been supported by the national major special projects for innovator drugs under the “12th Five-year Plan” of the Ministry of Science and Technology and won the 2017 Golden Award of Chinese Patents jointly issued by the State Intellectual Property Office and the World Intellectual Property Organization. The Phase II clinical trial has been competed for Azvudine, demonstrating the clear clinical advantages by right of its dual-target mechanism and low dose administration. The NDA has been submitted. In consideration of the enormous clinical demands unmet, the corresponding drug R&D projects go as planned, including the coming application for the clinical trial of the new drugs against lung cancer with proprietary intellectual property rights as well as the preclinical studies on the innovator drug candidates (e.g. the new drugs against cardiovascular and cerebrovascular diseases and the new long-acting oral anti-AIDS drugs). Henan Zhenshi Biotechnology Co., Ltd. strives for improving the living quality of human beings through the continuous pharmaceutical innovations.
About Yeedozencom
Yeedozencom is a professional and market-oriented service provider engaged in the full life-cycle management of drug research and development. Based on the rational cognition and deep expertise on the target products, Yeedozencom devotes itself to proposing the distinctive, proper and thoughtful solutions with warm concerns by experiencing and observing the challenges with Chinese characteristics in the full life cycle (e.g. R&D, manufacture, circulation and use) from the clients’ point of view. After years of accumulation, Yeedozencom has established and optimized the integrated service platform in support of the project operation management, clinical studies, registration services, biospecimen analysis, data management and statistics, aiming to minimize the time costs for pharmaceutical R&D, provide the value-added technical services and early launch the products to the market.
